Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE <b>Purpose:</b> Anaplastic lymphoma kinase (<i>ALK</i>) is the most frequently mutated oncogene in the pediatric cancer neuroblastoma. 27986745 2018
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. 28455243 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 AlteredExpression group BEFREE ALK gene rearrangements were identified in a variety of cancers, including neuroblastoma, where the presence of ALK expression is associated with adverse prognosis. 28338501 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE The currently recognized 2016 World Health Organization classification for RCC subtypes is briefly discussed, including new diagnostic entities (clear cell papillary RCC, hereditary leiomyomatosis and RCC-associated RCC, succinate dehydrogenase-deficient RCC, tubulocystic RCC, and acquired cystic disease-associated RCC) and areas of evolving RCC classification, such as transcription elongation factor B subunit 1 (TCEB1)-mutated RCC/RCC with angioleiomyoma-like stroma/RCC with leiomyomatous stroma, RCC associated with anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangement, thyroidlike follicular RCC, and RCC in neuroblastoma survivors. 27684973 2017
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE Bellini and colleagues demonstrate the importance of next-generation sequencing to uncover subclonal anaplastic lymphoma kinase (ALK) mutations in neuroblastoma. 26362998 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE These lines represent MYCN-amplified, NRAS and ALK mutant neuroblastoma subtypes respectively. 26517508 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. 26299615 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. 26554404 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE These data support clinical testing of crizotinib and conventional chemotherapy with the goal of integrating ALK inhibition into multiagent therapy for ALK-aberrant neuroblastoma patients. 26438783 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. 26059187 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. 25805801 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 AlteredExpression group BEFREE Non-CpG methylation observed essentially in clinically favorable cases was associated with the differentiation status of neuroblastoma and expression of key genes such as ALK. 26067621 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. 26747894 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. 26735175 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE GALNT14 is a member of the polypeptide N-acetylgalactosaminyl-transferase family and maps closely to ALK on 2p23.1, a region we previously discovered in linkage with NB in the family here considered. 26309160 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 CausalMutation group CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. 26687816 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. 26786851 2016
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE We discuss how the most recent structural and biological characterizations of ALK are directing preclinical and clinical studies of ALK inhibitors for both NSCLC and neuroblastoma. 26122839 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 AlteredExpression group BEFREE ALK pERKs up MYCN in neuroblastoma. 25351246 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. 24811913 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 AlteredExpression group BEFREE The pathogenetic role of PHOX2B in neuroblastoma (NB) is supported by mutations in familial, sporadic and syndromic cases of NB and overexpression of PHOX2B and its target ALK in tumor samples and NB cell lines. 25882494 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 GeneticVariation group BEFREE ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. 25517749 2015
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma
0.800 Biomarker group BEFREE ALK5' and ALK3' transcript patterns were established with qPCR for ALK-expressing controls including fusion-negative neuroblastomas, as well as fusion-positive anaplastic large cell lymphomas and NSCLC. 25153496 2015